IRC
PASG icon

Investors Research Corp’s Passage Bio PASG Stock Holding History

Investors Research Corp’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed -$69 – 1150
2022
Q4 		$69 Hold
3
– – ﹤0.01% 1123
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1121
2022
Q2 		$0 Hold
3
– – ﹤0.01% 1131
2022
Q1 		$0 Hold
3
– – ﹤0.01% 1075
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1027
2021
Q3 		$0 Hold
3
– – ﹤0.01% 1024
2021
Q2 		$1K Hold
3
– – ﹤0.01% 947
2021
Q1 		$1K Hold
3
– – ﹤0.01% 941
2020
Q4 		$1K Buy
3
+1
+50% +$400 ﹤0.01% 1041
2020
Q3 		$0 Buy
+2
New +$688 ﹤0.01% 1121

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Investors Research Corp's PASG Position: Q1 2023 in Review

Investors Research Corp sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 3 shares — an estimated $69 sold.

Investors Research Corp first reported a position in PASG in Q3 2020 and held it in 10 quarters. The position peaked at $1K in Q2 2021. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

  • Investors Research Corp reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
  • Investors Research Corp sold 3 Passage Bio shares in Q1 2023, an estimated $69.
  • Investors Research Corp first reported a position in Passage Bio in Q3 2020 and held it in 10 quarters.
  • Investors Research Corp's Passage Bio position peaked at $1K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on Investors Research Corp's 13F filing for Q1 2023, filed 11 May 2023.